Literature DB >> 28293022

Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma.

H Einsele1, S Knop1, M Vogel2, J Müller3, M Kropff4, B Metzner5, C Langer6, H Sayer7, W Jung8, H A Dürk9, H Salwender10, H Wandt11, F Bassermann12, M Gramatzki13, W Rösler14, H-H Wolf15, W Brugger16, M Engelhardt17, T Fischer18, P Liebisch6, C Straka19.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28293022     DOI： 10.1038/leu.2017.83

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  11 in total

1.  Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p.

Authors:  Kai Neben; Henk M Lokhorst; Anna Jauch; Uta Bertsch; Thomas Hielscher; Bronno van der Holt; Hans Salwender; Igor W Blau; Katja Weisel; Michael Pfreundschuh; Christof Scheid; Ulrich Dührsen; Walter Lindemann; Ingo G H Schmidt-Wolf; Norma Peter; Christian Teschendorf; Hans Martin; Mathias Haenel; Hans G Derigs; Marc S Raab; Anthony D Ho; Helgi van de Velde; Dirk Hose; Pieter Sonneveld; Hartmut Goldschmidt
Journal:  Blood       Date:  2011-12-08       Impact factor: 22.113

Review 2.  International Myeloma Working Group recommendations for global myeloma care.

Authors:  H Ludwig; J S Miguel; M A Dimopoulos; A Palumbo; R Garcia Sanz; R Powles; S Lentzsch; W Ming Chen; J Hou; A Jurczyszyn; K Romeril; R Hajek; E Terpos; K Shimizu; D Joshua; V Hungria; A Rodriguez Morales; D Ben-Yehuda; P Sondergeld; E Zamagni; B Durie
Journal:  Leukemia       Date:  2013-10-09       Impact factor: 11.528

3.  Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma.

Authors:  X Leleu; G Fouquet; B Hebraud; M Roussel; D Caillot; M L Chrétien; B Arnulf; R Szalat; L Garderet; L Benajiba; B Pegourie; C Regny; B Royer; A Caulier; A M Stoppa; S Garciaz; C Touzeau; C Chaleteix; J P Fermand; H A Loiseau; T Facon; M Attal; P Moreau
Journal:  Leukemia       Date:  2013-04-05       Impact factor: 11.528

4.  Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

Authors:  Pieter Sonneveld; Ingo G H Schmidt-Wolf; Bronno van der Holt; Laila El Jarari; Uta Bertsch; Hans Salwender; Sonja Zweegman; Edo Vellenga; Annemiek Broyl; Igor W Blau; Katja C Weisel; Shulamiet Wittebol; Gerard M J Bos; Marian Stevens-Kroef; Christof Scheid; Michael Pfreundschuh; Dirk Hose; Anna Jauch; Helgi van der Velde; Reinier Raymakers; Martijn R Schaafsma; Marie-Jose Kersten; Marinus van Marwijk-Kooy; Ulrich Duehrsen; Walter Lindemann; Pierre W Wijermans; Henk M Lokhorst; Hartmut M Goldschmidt
Journal:  J Clin Oncol       Date:  2012-07-16       Impact factor: 44.544

5.  International uniform response criteria for multiple myeloma.

Authors:  B G M Durie; J-L Harousseau; J S Miguel; J Bladé; B Barlogie; K Anderson; M Gertz; M Dimopoulos; J Westin; P Sonneveld; H Ludwig; G Gahrton; M Beksac; J Crowley; A Belch; M Boccadaro; M Cavo; I Turesson; D Joshua; D Vesole; R Kyle; R Alexanian; G Tricot; M Attal; G Merlini; R Powles; P Richardson; K Shimizu; P Tosi; G Morgan; S V Rajkumar
Journal:  Leukemia       Date:  2006-07-20       Impact factor: 11.528

6.  Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

Authors:  Philippe Moreau; Halyna Pylypenko; Sebastian Grosicki; Ievgenii Karamanesht; Xavier Leleu; Maria Grishunina; Grigoriy Rekhtman; Zvenyslava Masliak; Tadeusz Robak; Anna Shubina; Bertrand Arnulf; Martin Kropff; James Cavet; Dixie-Lee Esseltine; Huaibao Feng; Suzette Girgis; Helgi van de Velde; William Deraedt; Jean-Luc Harousseau
Journal:  Lancet Oncol       Date:  2011-04-18       Impact factor: 41.316

7.  Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.

Authors:  Michele Cavo; Lucia Pantani; Maria Teresa Petrucci; Francesca Patriarca; Elena Zamagni; Daniela Donnarumma; Claudia Crippa; Mario Boccadoro; Giulia Perrone; Antonietta Falcone; Chiara Nozzoli; Renato Zambello; Luciano Masini; Anna Furlan; Annamaria Brioli; Daniele Derudas; Stelvio Ballanti; Maria Laura Dessanti; Valerio De Stefano; Angelo Michele Carella; Magda Marcatti; Andrea Nozza; Felicetto Ferrara; Vincenzo Callea; Catello Califano; Annalisa Pezzi; Anna Baraldi; Mariella Grasso; Pellegrino Musto; Antonio Palumbo
Journal:  Blood       Date:  2012-04-12       Impact factor: 22.113

8.  Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial.

Authors:  Ulf-Henrik Mellqvist; Peter Gimsing; Oyvind Hjertner; Stig Lenhoff; Edward Laane; Kari Remes; Hlif Steingrimsdottir; Niels Abildgaard; Lucia Ahlberg; Cecilie Blimark; Inger Marie Dahl; Karin Forsberg; Tobias Gedde-Dahl; Henrik Gregersen; Astrid Gruber; Nina Guldbrandsen; Einar Haukås; Kristina Carlson; Ann Kristin Kvam; Hareth Nahi; Roald Lindås; Niels Frost Andersen; Ingemar Turesson; Anders Waage; Jan Westin
Journal:  Blood       Date:  2013-04-24       Impact factor: 22.113

9.  Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone.

Authors:  H Avet-Loiseau; J Soulier; J-P Fermand; I Yakoub-Agha; M Attal; C Hulin; L Garderet; K Belhadj; V Dorvaux; S Minvielle; P Moreau
Journal:  Leukemia       Date:  2010-01-14       Impact factor: 11.528

Review 10.  Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management.

Authors:  S Vincent Rajkumar
Journal:  Am J Hematol       Date:  2014-10       Impact factor: 10.047
View more
  6 in total

1.  Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation.

Authors:  R Chakraborty; E Muchtar; S K Kumar; F K Buadi; D Dingli; A Dispenzieri; S R Hayman; W J Hogan; P Kapoor; M Q Lacy; N Leung; R Warsame; T Kourelis; W Gonsalves; M A Gertz
Journal:  Leukemia       Date:  2017-08-14       Impact factor: 11.528

Review 2.  Fixed duration vs continuous therapy in multiple myeloma.

Authors:  Heinz Ludwig; Niklas Zojer
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

3.  The role of novel agents for consolidation after autologous transplantation in newly diagnosed multiple myeloma: a systematic review.

Authors:  Nico Gagelmann; Nicolaus Kröger
Journal:  Ann Hematol       Date:  2020-10-29       Impact factor: 3.673

4.  Venetoclax in combination with carfilzomib, doxorubicin and dexamethasone restores responsiveness in an otherwise treatment-refractory multiple myeloma patient.

Authors:  Sarolta Bojtine Kovacs; Jingting Luan; Sandra Maria Dold; Andreas Weis; Milena Pantic; Justus Duyster; Ralph Wäsch; Monika Engelhardt
Journal:  Haematologica       Date:  2019-08-29       Impact factor: 9.941

Review 5.  Insights on Multiple Myeloma Treatment Strategies.

Authors:  María-Victoria Mateos; Heinz Ludwig; Ali Bazarbachi; Meral Beksac; Joan Bladé; Mario Boccadoro; Michele Cavo; Michel Delforge; Meletios A Dimopoulos; Thierry Facon; Catarina Geraldes; Hartmut Goldschmidt; Roman Hájek; Markus Hansson; Krzysztof Jamroziak; Merav Leiba; Tamás Masszi; Larisa Mendeleeva; Michael O'Dwyer; Torben Plesner; Jesús F San-Miguel; Christian Straka; Niels W C J van de Donk; Kwee Yong; Samo Zver; Philippe Moreau; Pieter Sonneveld
Journal:  Hemasphere       Date:  2018-12-27

6.  Biological evaluation of both enantiomers of fluoro-thalidomide using human myeloma cell line H929 and others.

Authors:  Etsuko Tokunaga; Hidehiko Akiyama; Vadim A Soloshonok; Yuki Inoue; Hideaki Hara; Norio Shibata
Journal:  PLoS One       Date:  2017-08-01       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.